10-K/A: Solsence Restates 2024 Financials Amidst Inventory Accounting Errors

Solsence, Inc. (formerly Nanophase Technologies Corporation) has filed an amendment to its 2024 Form 10-K to restate its financial statements for the year ended December 31, 2024, due to material weaknesses in inventory costing and oversight.

Summary

• Solsence, Inc. (formerly Nanophase Technologies Corporation) has filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2024, to restate its previously issued consolidated financial statements.
• The restatement is due to errors identified in historical accounting for labor and overhead included in inventories, leading to overstatements of inventory and misstatements in cost of revenue, gross profit, and operating income.
• Material weaknesses were identified in inventory costing and in the oversight and review of financial reporting and restatement activities, indicating that internal controls were not effective as of December 31, 2024.
• The company has implemented remediation plans to address these control deficiencies.
• Total revenue increased to $52.3 million in 2024 from $37.3 million in 2023, driven by consumer products, though personal care ingredients and advanced materials saw decreases.
• Gross profit increased to $13.1 million in 2024 from $7.3 million in 2023, with gross margin improving to 24.9% from 19.5%.
• Net income for 2024 was $1.1 million, a significant improvement from a net loss of $4.9 million in 2023.
• The company raised $6 million in March 2024 through the issuance of Series X Preferred Stock to Strandler, LLC, which was subsequently converted into common stock.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the significant restatement of financial statements, material weaknesses in internal controls, and the resulting impact on reported figures, despite some revenue growth.

Positives

• Total revenue increased by approximately 40.3% to $52.3 million in 2024 from $37.3 million in 2023.
• Gross profit increased by approximately 79.3% to $13.1 million in 2024 from $7.3 million in 2023.
• Gross margin improved to 24.9% in 2024 from 19.5% in 2023.
• The company reported a net income of $1.1 million in 2024, a substantial improvement from a net loss of $4.9 million in 2023.
• Net cash provided by operating activities was $1.97 million in 2024, a significant turnaround from a net cash used of $2.01 million in 2023.
• The company successfully raised $6 million in March 2024 through the issuance of Series X Preferred Stock.

Negatives

• The company is restating its previously issued consolidated financial statements for the years ended December 31, 2023 and 2024, due to material errors in inventory costing.
• Material weaknesses were identified in internal controls over financial reporting, specifically in inventory costing and in the oversight and review of financial reporting and restatement activities.
• Inventories were overstated, and cost of revenue was understated as a result of the accounting errors.
• The restatement resulted in a decrease in net inventories by $4.65 million and $1.52 million as of December 31, 2024 and 2023, respectively.
• Cost of revenue increased by $3.14 million for 2024 and $0.55 million for 2023 due to the restatement.
• The company's disclosure controls and procedures were not effective as of December 31, 2024, due to the identified material weaknesses.

Risks

• The identified material weaknesses in internal controls could lead to future misstatements in financial reporting.
• The company's reliance on a few significant customers (52% of revenue in 2024) poses a risk if any of these customers are lost.
• There is a risk associated with exclusive supply agreements with BASF, where failure to meet performance requirements could lead to the sale of production equipment to BASF and loss of significant revenue.
• The company faces potential limitations on the utilization of its net operating loss carryforwards due to potential future ownership changes.
• Inflationary pressures on supplier prices and wages are expected to have a material effect on operations and financial position in 2025 and beyond.
• The company's ability to pass on cost increases to customers may be limited by contractual limitations or market conditions, potentially reducing margins and net income.

Future Outlook

The company expects to continue new materials development and dispersion technologies for personal care applications and formulated Solsence products during 2025 and beyond. Management believes its current fixed manufacturing cost structure is sufficient to support higher revenue volumes. Margin growth will depend on revenue mix, volume, cost-cutting, passing on raw material increases, and scaling production. Research and development expenses are expected to increase slightly in 2025, dependent on the success of the Solsence line. Selling, general, and administrative expenses are expected to be slightly higher in 2025 due to administrative function expansion. Management anticipates inflationary cost increases in 2025, but aims to offset them through production efficiencies and price increases where possible.

Management Comments

• We believe that our current fixed manufacturing cost structure is sufficient to support higher levels of revenue volume.
• The extent to which margins grow, as a percentage of total revenue, will be dependent upon revenue mix, revenue volume, our ability to cut costs and pass commodity market-driven raw materials increases on to customers, and the speed and efficiency with which we are able to scale up production for our Solsence products.
• We expect that, as product revenue volume increases, our fixed manufacturing costs will be more efficiently absorbed, which should lead to increased margins as we grow.
• We expect supplier price increases and wage and benefit inflation, both of which represent a significant component of our costs of operations, may have a material effect on our operations and financial position in 2025 and beyond.
• Management believes that current liquidity and expected borrowing capacity are sufficient to fund operations and substantial doubt is not raised regarding the Company's ability to continue as a going concern.

Industry Context

StockSavvy.ai notes that Solsence operates in the health-oriented, science-driven skin health and beauty markets, leveraging mineral-based UV protection and proprietary APIs. The company also serves legacy markets in advanced materials. The restatement highlights common challenges in inventory accounting, particularly for companies with complex manufacturing processes involving labor and overhead allocation. The focus on skin health and advanced materials aligns with broader industry trends in personalized care and specialized material applications.

Comparison to Industry Standards

• The restatement of financial statements due to inventory costing errors is a significant deviation from standard accounting practices and indicates a failure in internal controls, which is a critical area for investor confidence.
• The company's gross margin of 24.9% in 2024, while improved, may need to be compared against industry benchmarks for specialty chemical or consumer product ingredient manufacturers to assess its competitiveness.
• The material weaknesses in internal controls, particularly in inventory costing and financial reporting oversight, are serious concerns that are not typical of well-managed public companies and suggest a need for significant improvement to meet industry standards for corporate governance.
• The company's reliance on a few large customers (52% of revenue) is a common characteristic in some B2B industries but can be a risk factor compared to companies with more diversified customer bases.

Corporate Governance

Related Party Transactions

• The company has several loan agreements and lines of credit with Beachcorp, LLC and Strandler, LLC, which are affiliates of Mr. Bradford T. Whitmore, the majority beneficial owner of the Company's common stock and brother of director R. Janet Whitmore.
• These related party transactions include an Amended and Restated Business Loan Agreement (A&R Loan Agreement), an Inventory Facility, and a New Term Loan Agreement.
• The company issued Series X Preferred Stock to Strandler, LLC in March 2024, which was subsequently converted into common stock.
• Interest expense related to these parties was $656,000 in 2024 and $770,000 in 2023.
• Outstanding balances with Beachcorp, LLC were $4,000,000 as of December 31, 2024, and $7,810,000 as of December 31, 2023.
• Outstanding balances with Strandler, LLC were $1,000,000 as of December 31, 2024, and $3,000,000 as of December 31, 2023.

Stakeholder Impact

• Shareholders: The restatement of financial statements and identification of material weaknesses in internal controls negatively impacts investor confidence and may affect share price.
• Creditors: The company's debt structure and maturity dates have been extended, and waivers were provided for certain defaults related to the inventory facility, which could impact creditor confidence.
• Employees: The company acknowledges that a significant event related to the BASF agreement could result in the loss of key staff and line employees, and that hiring and retaining skilled employees could be difficult.
• Customers: The company's reliance on key customers and potential loss of significant revenue from the BASF agreement could impact supply chain stability.

Next Steps

• Implement remediation measures for inventory costing, including reassessing methodologies, refining cost pools, strengthening documentation, and enhancing management review.
• Implement remediation measures for financial reporting oversight, including enhancing executive oversight, improving review of third-party specialists, and increasing involvement of personnel with appropriate expertise.
• Continue to focus on reducing controllable variable product manufacturing costs.
• Continue new materials development and dispersion technologies for personal care applications and Solsence products.
• Expand marketing and sales efforts relating to Solsence products.
• Seek recovery of remaining erroneously awarded incentive compensation from executive officers in accordance with the Clawback Policy.

Key Dates

Recommendation

The company has shown revenue growth and improved gross margins, turning a net loss into a profit. However, the significant restatement of financial statements due to material weaknesses in internal controls over inventory costing and financial reporting oversight introduces substantial risk and uncertainty. While the company is addressing these issues, the impact on future reliability of financial reporting and the potential for further issues warrants a cautious 'hold' stance until the effectiveness of remediation efforts is demonstrated over time.

Keywords

inventory accounting, financial restatement, internal controls, material weakness, cost of revenue, consumer products, skin health, preferred stock